Psychiatry Practice Software

Psychiatry practices focus on medication management for mental health conditions. Initial psychiatric evaluations require 60-90 minutes for comprehensive assessment. Follow-up medication management visits are typically 15-30 minutes. The between-visit period is where medication effects manifest, side effects emerge, and symptoms change — yet this period traditionally has no visibility or revenue.

Medication adherence determines treatment success more than any other factor. Patients who do not take medications as prescribed cannot benefit from them. Non-adherence rates in psychiatry exceed 50% for many conditions. Traditional practice discovers non-adherence only when patients admit it during visits or when treatment fails. RTM monitoring through the clinIQ app provides visibility into adherence between visits.

Symptom patterns between visits inform medication decisions. A patient stable at their monthly visit but whose daily symptom tracking reveals weekly cycling may need different medication than someone truly stable. Without between-visit data, psychiatrists rely on patient recall which is often incomplete or inaccurate. RTM data collection creates the longitudinal picture necessary for optimal medication management.

Telehealth is particularly well-suited to psychiatry medication management. Follow-up visits focused on symptom review, side effect assessment, and medication adjustment do not require physical examination. Video visits through the clinIQ app provide access for patients in rural areas, those with transportation barriers, or those who prefer the convenience of video.

Coordination with behavioral health therapy providers creates comprehensive care. The therapist observes symptoms and function during weekly sessions. The psychiatrist manages medications based partly on therapist observations. Secure messaging and shared RTM data visibility enable this coordination.

RTM billing for psychiatry uses CPT 98976 for mental and behavioral health device supply plus 98980 and 98981 for treatment management time. This captures revenue for the between-visit monitoring that quality psychiatric care requires.

Qualifying conditions span psychiatric diagnoses requiring medication management including major depressive disorder, generalized anxiety disorder, bipolar disorder, schizophrenia, PTSD, OCD, and ADHD. The monitoring must be therapeutically meaningful, not just billing activity.

Patient-reported data collection through the clinIQ app captures mood ratings using validated scales, medication adherence logging, side effect reporting, sleep quality and patterns, anxiety levels and triggers, and energy and motivation ratings. Patients complete brief daily or weekly entries taking two to three minutes.

The revenue calculation shows $120-150 per enrolled patient monthly. One hundred patients enrolled generates $12,000-15,000 monthly or $144,000-180,000 annually. Psychiatric patients on medication maintenance are prime candidates with typical enrollment achievable at 60-70% of eligible patients.

Over 40% of Medicare RTM patients miss at least one required billing component (HHS OIG, 2024). The clinIQ app achieves 75%+ compliance through push notification reminders, simple entry interfaces, and the clinical relationship reinforcing tracking value.

Wearable integration adds objective data. Sleep patterns from Oura Ring or Apple Watch correlate strongly with psychiatric symptoms. Activity levels indicate behavioral activation or withdrawal. This passive data supplements self-reports without adding patient burden.

Medication adherence in psychiatry is notoriously poor with 40-60% non-adherence rates for many psychiatric medications. Patients stop medications when feeling better, when side effects occur, when they forget, or due to ambivalence about treatment.

Adherence tracking through the clinIQ app creates visibility into medication-taking behavior. Patients log when they take medications. The system tracks adherence rates over time. Patterns emerge showing whether patients take medications consistently, miss weekend doses, or have stopped entirely.

Reminder functionality helps patients remember medications through push notifications at scheduled dosing times. The reminder links to the logging function for easy dose confirmation. For patients whose adherence problem is forgetting, reminders solve the problem directly.

Adherence visualization in the psychiatrist dashboard shows compliance patterns. Before a medication management visit, the psychiatrist sees whether the patient has been adherent. A patient reporting medication is not working whose adherence data shows 40% compliance needs a different conversation than an adherent patient not responding to adequate trials.

Non-adherence intervention through secure messaging addresses problems early. When adherence drops, staff can message the patient to understand barriers. Is it side effects? Forgetting? Ambivalence? Understanding the reason guides intervention.

Side effect correlation with adherence reveals patterns. A patient whose adherence drops after starting a new medication may be experiencing intolerable side effects they have not reported. The timing correlation visible in RTM data prompts investigation.

Telehealth is exceptionally well-suited to psychiatry medication management visits. Follow-up visits involve symptom review, side effect assessment, and medication decision-making — none requiring physical examination.

Patient access improves dramatically with telehealth. Psychiatric provider shortages affect many regions. Patients with depression may struggle to mobilize for in-person visits. Patients with anxiety may find office visits stressful. Video visits through the clinIQ app remove these barriers.

Session integration means telehealth uses the same platform patients use for check-in, messaging, and symptom tracking. Patients tap to join from a familiar interface rather than navigating separate platforms.

RTM data review during telehealth visits is natural. The psychiatrist has symptom trends and medication adherence data visible while talking with the patient. Discussion references specific data points from tracking.

Reimbursement for psychiatric telehealth remains strong. Twenty-four states have payment parity laws according to CCHP 2025 data. Medicare telehealth flexibilities extend through 2027.

A hybrid model using in-person initial evaluations and telehealth follow-ups optimizes both clinical care and access. Scheduling through the patient app shows both telehealth and in-person options.

Between-visit symptom tracking through the clinIQ app provides longitudinal data necessary for optimal medication management. Point-in-time assessment at monthly visits misses patterns characterizing psychiatric conditions.

Mood tracking using validated instruments like PHQ-9 or GAD-7 provides standardized measurement over time. Patients complete brief assessments on schedule. The data trends in the psychiatrist dashboard, showing response to medication changes, seasonal patterns, or life stress impacts.

Depression-specific tracking captures energy levels, sleep quality, appetite changes, concentration, and anhedonia. Different symptom profiles may suggest different medication approaches.

Anxiety-specific tracking captures worry intensity, physical symptoms, avoidance behaviors, and specific triggers. Tracking distinguishes patterns that guide treatment.

Bipolar tracking captures both depression and elevation symptoms. Sleep duration changes often precede mood episodes. Energy level fluctuations indicate emerging episodes. This tracking enables intervention before full episodes develop.

Wearable integration adds objective data. Sleep duration and quality from Apple Watch or Oura Ring correlates with psychiatric symptoms. Activity levels indicate behavioral activation or withdrawal. This passive data complements patient-reported symptoms.

Alert thresholds trigger notification when tracking data indicates concerning changes. Significant PHQ-9 score increases or reported suicidal ideation can alert clinical staff for secure messaging follow-up or earlier telehealth visits.

Psychiatric medication management works best when coordinated with therapy and primary care. The psychiatrist manages medications based partly on observations from other providers who see the patient more frequently.

Behavioral health therapy coordination is essential for patients receiving both medication and psychotherapy. Therapist observations about symptom severity, function, and medication effects inform psychiatric decision-making. Secure messaging provides a communication channel. Shared RTM data visibility means both providers see consistent patient-reported information.

Primary care coordination addresses medical issues that interact with psychiatric treatment. Thyroid function affects mood. Medication interactions require attention. Secure file exchange shares relevant documentation.

Addiction medicine coordination matters for patients with co-occurring substance use disorders. Some psychiatric medications carry addiction risk. Coordinated treatment addresses both conditions. Shared RTM data showing mood, cravings, and substance use informs both providers.

Pain management coordination addresses the common overlap between chronic pain and mental health. Depression worsens pain perception. Coordinated management avoids conflicting treatments.

Emergency coordination ensures crisis situations receive appropriate response. When RTM tracking reveals acute deterioration, coordination with emergency services may be necessary.

Psychiatry prescribes controlled substances for ADHD, anxiety, and sleep disorders. These prescriptions require additional tracking and compliance measures.

PDMP verification must occur before controlled substance prescriptions according to state requirements. The patient flow workflow can document that PDMP checks occurred, though actual verification happens in the state portal. Compliance tracking creates audit trail for regulatory review.

Stimulant monitoring for ADHD patients on medications like amphetamines or methylphenidate includes tracking effectiveness, side effects, appetite, sleep impact, and appropriate use. RTM data collection captures these parameters systematically.

Benzodiazepine monitoring for anxiety tracks both therapeutic benefit and risk factors for dependence. Duration of use, dose stability, and any concerning patterns appear in tracking data.

Sleep medication monitoring for patients on controlled sleep aids tracks effectiveness and appropriate use patterns.

Prescription tracking documents controlled substance prescriptions with quantities and dates. This documentation supports practice compliance with regulatory requirements.

Analytics can report on controlled substance prescribing patterns, supporting quality improvement and regulatory compliance.

Psychiatry implementation focuses on RTM enrollment for medication management patients, telehealth integration, medication adherence tracking, and symptom monitoring configuration.

Week one maps clinical workflows including evaluation scheduling, follow-up patterns, between-visit communication, and coordination with therapists. Scheduling templates configure for initial evaluations and medication management visits. RTM data collection configures for mood, adherence, and side effects.

Week two trains psychiatrists on dashboard, RTM data review, telehealth session management, and adherence monitoring. Staff trains on scheduling, check-in, and patient enrollment.

Week three goes live with telehealth sessions, RTM enrollment beginning, and adherence tracking activation.

ROI sources include RTM billing revenue at $120-150 per enrolled patient monthly with 100 patients generating $140,000+ annually. Telehealth expands patient reach. Adherence monitoring improves treatment outcomes. Better outcomes reduce emergency utilization and crisis interventions.

Professional tier at $499 monthly includes RTM, telehealth, scheduling, secure messaging, wearable integration, and analytics. RTM revenue from 40 enrolled patients exceeds annual platform cost.